



## Notice of Early Redemption - €350 million € 1.875% fixed rate notes due 2 April 2022

**Brussels (Belgium), 14 April 2021 – 07.00 am (CEST) – regulated information** - UCB SA/NV announces its intention to redeem the €350,000,000 1.875 per cent fixed rate notes due 2 April 2022 (the "Notes") in whole in accordance with the Condition 5(d) of the Prospectus (Redemption at the Option of the Issuer (Issuer Call)). UCB takes this action in the context of its active liability management.

The Notes will be redeemed on 29 April 2021 (the "Optional Redemption Date") at their Optional Redemption Amount together with any accrued and unpaid interest up to, but excluding, the Optional Redemption Date.

The Optional Redemption Amount, calculated by the Calculation Agent on the basis of the Reference Rate on 12 April 2021 at 11.00 am, is 101.90451% of the Calculation Amount (€100,000). The accrued and unpaid interest is 0.13870% of the Calculation Amount.

This notice is irrevocable and shall be governed by Belgian law.

### **Further information**

This press release and the prospectus dated 10 March 2015, in relation with the issue of €350,000,000 1.875 per cent fixed rate notes due 2 April 2022, are available on UCB SA/NV's website via the following [link](#).

### **Contact information**

Antje Witte,  
Investor Relations, UCB  
T +32 2 559 94 14,  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

### **About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB\\_news](https://twitter.com/UCB_news)